Nilotinib Teva (Nilotinib)

Nilotinib blocks the activity of the BCR‑ABL tyrosine kinase, including many mutant forms that are not inhibited by imatinib. By preventing this enzyme from signaling, the drug stops the proliferation of leukemic cells and promotes their programmed death, thereby controlling disease progression.

The dosage of Nilotinib Teva is determined by the prescribing physician based on the individual patient's clinical condition, prior therapy, and tolerance. Only a qualified healthcare professional can set the appropriate dose and schedule.

Nilotinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while taking nilotinib because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that retains activity against many imatinib‑resistant mutations. Compared with first‑generation agents, it often provides deeper molecular responses but may have a different safety profile, including a higher risk of QT prolongation, requiring individualized risk‑benefit assessment.

Store Nilotinib Teva tablets at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency.

Nilotinib Teva is taken orally, usually as whole tablets with a low‑fat meal. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider, ensuring consistent timing with respect to meals.

The most serious adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe neutropenia that raises infection risk, and pancreatitis. Patients should be monitored regularly for cardiac, hematologic and pancreatic abnormalities.

Nilotinib should be avoided in patients with a known hypersensitivity to the drug, those with a prolonged QT interval, uncontrolled cardiac disease, or severe hepatic impairment. It is also contraindicated during pregnancy and should be used with caution in breastfeeding women.